This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RG7426, BHT-3021
Description: BHT-3021 is a plasmid encoding proinsulin, in order to tolerize the immune system to proinsulin, inhibiting the attack on this self-antigen in diabetes.
Deal Structure: In June 2009, Bayhill Therapeutics announced that it entered into an exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech, a wholly-owned member of the Roche Group.
Under the terms of the agreement, Genentech will make an upfront payment of $25M in cash and equity, with additional development, regulatory and sales milestone payments potentially exceeding $325M. Bayhill will also receive competitive escalating royalties on annual net sales. Bayhill will be responsible for completing the Phase I/II trial, while Genentech will be responsible for all future research, development, manufacturing and commercialization efforts. Genentech will reimburse Bayhill the remaining costs of the Phase I/II trial and will fund all future expenses. Under the terms of the agreement, Bayhill retains rights to opt-in on future development as well as an option to co-promote in North America.
In February 2011, Roche announced rights to...See full deal structure in Biomedtracker
Additional information available to subscribers only: